JPH0123462B2 - - Google Patents

Info

Publication number
JPH0123462B2
JPH0123462B2 JP54043119A JP4311979A JPH0123462B2 JP H0123462 B2 JPH0123462 B2 JP H0123462B2 JP 54043119 A JP54043119 A JP 54043119A JP 4311979 A JP4311979 A JP 4311979A JP H0123462 B2 JPH0123462 B2 JP H0123462B2
Authority
JP
Japan
Prior art keywords
group
represents hydrogen
formula
oxy
carbazolyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP54043119A
Other languages
English (en)
Japanese (ja)
Other versions
JPS54157558A (en
Inventor
Uiideman Furitsutsu
Kamupe Uorufugangu
Teiiru Matsukusu
Shuhooneru Jisuberuto
Retsushu Egon
Deiitoman Kaaru
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Boehringer Mannheim GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6036838&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JPH0123462(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Mannheim GmbH filed Critical Boehringer Mannheim GmbH
Publication of JPS54157558A publication Critical patent/JPS54157558A/ja
Publication of JPH0123462B2 publication Critical patent/JPH0123462B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/64—Oxygen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP4311979A 1978-04-13 1979-04-11 Novel carbazolyll*4**oxyypropanolamine derivative*its manufacture and drug containing it and having vasodilatation and*or betaaacceptor occlusion activity Granted JPS54157558A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19782815926 DE2815926A1 (de) 1978-04-13 1978-04-13 Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel

Publications (2)

Publication Number Publication Date
JPS54157558A JPS54157558A (en) 1979-12-12
JPH0123462B2 true JPH0123462B2 (OSRAM) 1989-05-02

Family

ID=6036838

Family Applications (2)

Application Number Title Priority Date Filing Date
JP4311979A Granted JPS54157558A (en) 1978-04-13 1979-04-11 Novel carbazolyll*4**oxyypropanolamine derivative*its manufacture and drug containing it and having vasodilatation and*or betaaacceptor occlusion activity
JP62076548A Pending JPS63258416A (ja) 1978-04-13 1987-03-31 カルバゾリル−（４）−オキシ−プロパノ−ルアミン誘導体を含有し血管拡張作用及び／又はβ−受容体閉塞作用を有する薬剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP62076548A Pending JPS63258416A (ja) 1978-04-13 1987-03-31 カルバゾリル−（４）−オキシ−プロパノ−ルアミン誘導体を含有し血管拡張作用及び／又はβ−受容体閉塞作用を有する薬剤

Country Status (23)

Country Link
US (1) US4503067A (OSRAM)
EP (1) EP0004920B1 (OSRAM)
JP (2) JPS54157558A (OSRAM)
AT (1) AT375639B (OSRAM)
AU (1) AU522975B2 (OSRAM)
BG (1) BG61419B2 (OSRAM)
CA (1) CA1129416A (OSRAM)
CS (2) CS227007B2 (OSRAM)
DD (1) DD143607A5 (OSRAM)
DE (2) DE2815926A1 (OSRAM)
DK (1) DK154555C (OSRAM)
ES (1) ES479396A1 (OSRAM)
FI (1) FI70406C (OSRAM)
HK (1) HK2385A (OSRAM)
HU (1) HU179433B (OSRAM)
IL (1) IL57020A (OSRAM)
LT (1) LT2628B (OSRAM)
LU (1) LU88320I2 (OSRAM)
MX (1) MX9203380A (OSRAM)
NL (1) NL930110I2 (OSRAM)
SG (1) SG52284G (OSRAM)
SU (1) SU810079A3 (OSRAM)
ZA (1) ZA791732B (OSRAM)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3131146A1 (de) * 1981-08-06 1983-02-24 Boehringer Mannheim Gmbh, 6800 Mannheim Neue heteroaryloxypropanolamine, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3300933A1 (de) * 1983-01-13 1984-07-19 Boehringer Mannheim Gmbh, 6800 Mannheim Verwendung von d,l- und d-carazolol als antiglaukommittel sowie arzneimittel, die diese stoffe enthalten
DE3319027A1 (de) * 1983-05-26 1984-11-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur herstellung von optisch aktiven carbazol-derivaten, neue r- und s-carbazol-derivate, sowie arzneimittel, die diese verbindungen enthalten
GB9113802D0 (en) * 1991-06-26 1991-08-14 Smithkline Beecham Plc Medicaments
US5405863A (en) * 1992-12-01 1995-04-11 Smithkline Beecham Corporation Antioxidant cardioprotective use of, and method of treatment using, hydroxycarbazole compounds
ZA938897B (en) * 1992-12-01 1994-08-01 Smithkline Beecham Corp Antioxidant neuroprotective use of and method of treatment using hydroxycarbazole compounds
US5308862A (en) * 1993-03-05 1994-05-03 Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Beecham Corp., Ltd. Partnership No. 1 Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation
WO1994020096A1 (en) * 1993-03-05 1994-09-15 Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Beckman Corporation Limited Method of employing carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation
US5393772A (en) * 1993-11-24 1995-02-28 Boehringer Mannheim Pharmaceuticals Corporation Use of, and method of treatment using, hydroxycarbazole compounds for inhibition of smooth muscle migration and proliferation
US5760069A (en) 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
US6075040A (en) * 1996-09-05 2000-06-13 Eli Lilly And Company Selective β3 adrenergic agonists
ZA967892B (en) * 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
US6177430B1 (en) 1997-03-27 2001-01-23 Pfizer Inc Use of α1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
DE19628335A1 (de) * 1996-07-13 1998-01-15 Boehringer Mannheim Gmbh Verwendung von Carbazolyl-(4)-oxy-propanolamin-Derivaten zur topischen Behandlung von peripheren Durchblutungsstörungen
BR9711228A (pt) * 1996-08-23 2000-01-11 Boeringer Mannheim Pharmaceuti Método para a inibição da expressão de fas
EP0827746B1 (en) * 1996-09-05 2002-04-03 Eli Lilly And Company Carbazole analogues as selective beta3 adrenergic agonists
CN1157188C (zh) * 1996-10-09 2004-07-14 泊灵格曼海姆药品公司 抑制应激活化蛋白激酶的方法
EP0893440A1 (en) * 1997-07-22 1999-01-27 Roche Diagnostics GmbH Thermodynamically stable modification of 1-(4-carbazolyloxy)-3-[2-(2-methoxyphenoxy)ethylamino]-2-propanole, process for its preparation and pharmaceutical compositions containing it
US6730326B2 (en) 1997-07-22 2004-05-04 Roche Diagnostics Gmbh Thermodynamically stable modification of 1-(4-carbazolyl-oxy-3[2-(2-methoxyphenoxy)-ethylamino]-2-propanol process for its preparation and pharmaceutical compositions containing it
ZA989365B (en) * 1997-10-15 1999-04-15 Boehringer Mannheim Pharm Corp Preparation for treating alzheimer's disease
WO1999024017A1 (en) * 1997-11-12 1999-05-20 Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Bechman Corporation Limited Partnership No.1 Novel oral dosage form for carvedilol
HU9702209D0 (en) * 1997-11-24 1998-01-28 Egyt Gyogyszervegyeszeti Gyar Process for producing pharmaceutical product
HU227441B1 (en) * 1997-11-24 2011-06-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Process for producing carvedilol, enantiomers and salts thereof
CO5011072A1 (es) * 1997-12-05 2001-02-28 Lilly Co Eli Etanolaminas pirazinil substituidas como agfonistas de los receptores
EP0968714A1 (de) * 1998-07-02 2000-01-05 Roche Diagnostics GmbH Verfahren zur Herstellung schnellauflösender pharmazeutischer Zubereitungen von schwerlöslichen Wirkstoffen
JP3947654B2 (ja) * 1998-04-09 2007-07-25 ロシュ ダイアグノスティックス ゲーエムベーハー カルベジロール製剤
DE19833119A1 (de) * 1998-07-23 2000-01-27 Roche Diagnostics Gmbh Spritzfertige Injektionslösungen enthaltend Carvedilol
US6664284B2 (en) 1998-07-23 2003-12-16 Roche Diagnostics Gmbh Stabilized carvedilol injection solution
AU5251999A (en) 1998-08-04 2000-02-28 Wisconsin Alumni Research Foundation Method of reducing retinal ganglion cell degeneration
PE20001302A1 (es) 1998-11-27 2000-11-30 Hoffmann La Roche Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida
MY125942A (en) 1999-09-07 2006-09-29 Upjohn Co Aminoalkoxy carbazoles for the treatment of cns diseases
JP2003514019A (ja) 1999-11-15 2003-04-15 スミスクライン・ビーチャム・コーポレイション カルベジロールメタンスルホン酸塩
ES2227206T3 (es) * 2000-04-03 2005-04-01 F. Hoffmann-La Roche Ag Soluciones concentradas de carvedilol.
US20010036959A1 (en) * 2000-04-03 2001-11-01 Gabel Rolf Dieter Carvedilol-hydrophilic solutions
DK174645B1 (da) * 2000-05-18 2003-08-04 Gea Farmaceutisk Fabrik As Fremgangsmåde og mellemprodukter til fremstillingen af 1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxy-phenoxy)-ethylamino]-propan-2-ol, carvedilol og syreadditionssalte deraf
EP1655285A1 (en) * 2000-06-28 2006-05-10 Teva Pharmaceutical Industries Ltd. Method for preparation of a crystalline form of carvedilol (form II)
US6699997B2 (en) * 2000-06-28 2004-03-02 Teva Pharmaceutical Industries Ltd. Carvedilol
GB0106953D0 (en) * 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
JP2004525941A (ja) * 2001-04-02 2004-08-26 スミスクライン・ビーチャム・コーポレイション 治療方法
IN191028B (OSRAM) * 2001-05-17 2003-09-13 Sun Pharmaceutical Ind Ltd
JP2004534840A (ja) * 2001-07-13 2004-11-18 スミスクライン・ビーチャム・コーポレイション カルベジロール多型体
WO2003017046A2 (en) * 2001-08-14 2003-02-27 Variant Holdings, Llc. System for marketing goods and services utilizing computerized central and remote facilities
WO2003024429A1 (en) 2001-09-21 2003-03-27 Egalet A/S Polymer release system
WO2003024430A1 (en) 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
CN1308307C (zh) * 2001-09-28 2007-04-04 弗·哈夫曼-拉罗切有限公司 假多晶型的卡维地洛
WO2003028718A1 (en) * 2001-10-01 2003-04-10 Smithkline Beecham Corporation Novel formulations of carvedilol
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
HRP20040673A2 (en) 2002-01-15 2005-06-30 Teva Pharmaceutical Industries Ltd. Crystalline solids of carvedilol and processes for their preparation
KR20040088519A (ko) 2002-02-22 2004-10-16 뉴 리버 파마슈티칼스, 인크. 활성 제제 전달 시스템 및 활성 제제의 보호 및 투여 방법
WO2003092622A2 (en) * 2002-04-30 2003-11-13 Sb Pharmco Puerto Rico Inc. Carvedilol monocitrate monohydrate
US20050261335A1 (en) * 2002-05-03 2005-11-24 Wei Chen Carvedilol formulations
EP1501502A2 (en) * 2002-05-03 2005-02-02 SmithKline Beecham Pharmco Puerto Rico, Inc. Carvedilol pharmasolve solvate
EA008384B1 (ru) * 2002-06-27 2007-04-27 Эс Би ФАРМКО ПУЭРТО РИКО ИНК. Фосфатные соли карведилола, их сольваты, композиции и способы лечения гипертензии, застойной сердечной недостаточности или стенокардии
EP1539140A4 (en) 2002-06-27 2005-12-07 Sb Pharmco Inc CARVEDILOLHYDOBROMID
US20040152756A1 (en) * 2002-07-15 2004-08-05 Wei Chen Carvedilol polymorph
AU2003256089A1 (en) * 2002-07-22 2004-02-09 Nanohybrid Co., Ltd. Hybrid of itraconazole, cyclosporine or carvedilol with a layered silicate and a process for preparing the same
GEP20074134B (en) 2002-08-19 2007-06-25 Pfizer Prod Inc Combination therapy for hyperproliferative diseases
US6632832B1 (en) 2002-09-10 2003-10-14 Dabur Research Foundation Anti-cancer activity of carvedilol and its isomers
SK285547B6 (sk) * 2002-11-08 2007-03-01 Zentiva, A. S. Spôsob prípravy Carvedilolu
AU2003275953A1 (en) * 2002-11-08 2004-06-07 Egalet A/S Controlled release carvedilol compositions
US7468442B2 (en) * 2003-04-21 2008-12-23 Matrix Laboratories Ltd. Process for the preparation of carvedilol form-II
EP1658283A2 (en) * 2003-05-30 2006-05-24 Ranbaxy Laboratories, Ltd. Substituted pyrrole derivatives and their use as hmg-co inhibitors
US7482471B2 (en) * 2003-06-20 2009-01-27 Sun Pharmaceutical Industries Limited Process for preparation of 1-[9H-carbazol-4-yloxy]-3-[{2-(2-(-methoxy)phenoxy)-ethyl}-amino]-propan-2-ol
US20050037063A1 (en) * 2003-07-21 2005-02-17 Bolton Anthony E. Combined therapies
EP1686967A4 (en) * 2003-11-25 2012-08-08 Smithkline Beecham Cork Ltd CARVEDILOL-FREE BASE, SALTS, WATER-FREE FORMS OR SOLVATES THEREOF, CORRESPONDING PHARMACEUTICAL COMPOSITIONS, CONTROLLED RELEASE FORMULAS AND TREATMENT OR DISPOSAL PROCEDURES
US7750036B2 (en) * 2003-11-25 2010-07-06 Sb Pharmco Puerto Rico Inc. Carvedilol salts, corresponding compositions, methods of delivery and/or treatment
EP1691789B1 (en) 2003-11-25 2017-12-20 SmithKline Beecham (Cork) Limited Carvedilol free base, salts, anhydrous forms or solvate thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
US20070191456A1 (en) * 2004-04-22 2007-08-16 Tarur Venkatasubramanian R Novel process for the preparation of 1-(9h-carbazol-4-yloxy)-3-[[2-(-methoxyphenoxy)-ethyl] amino]-propan-2-ol
GB0411273D0 (en) * 2004-05-20 2004-06-23 Cipla Ltd Process and product
JP2008521805A (ja) * 2004-11-30 2008-06-26 アーテシアン セラピューティクス， インコーポレイテッド β−アドレナリン作用性受容体およびホスホジエステラーゼに対する阻害活性を有する強心性化合物
WO2006061364A1 (en) * 2004-12-09 2006-06-15 Zach System S.P.A. Process for the preparation of carvedilol and its enantiomers
US20070027202A1 (en) * 2005-06-07 2007-02-01 Ashok Kumar Process for the preparation of carvedilol and its salts
KR20070088507A (ko) * 2005-06-09 2007-08-29 테바 파마슈티컬 인더스트리즈 리미티드 카베딜올의 결정질 형태 및 이것의 제조 방법
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
ZA200803226B (en) 2005-10-13 2009-11-25 Orchid Res Lab Ltd Heterocyclic Compounds as Pstat3/IL-6 Inhibitors
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
BRPI0618379A2 (pt) * 2005-11-08 2011-08-30 Ranbaxy Lab Ltd processo para preparação do hemi-sal de cálcio do ácido (3r,5r) -7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroxime tilfenilamino) carbonil]-pirrol-1-il] -3, 5-diidroxi heptanóico
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
AR059838A1 (es) * 2006-03-14 2008-04-30 Ranbaxy Lab Ltd Formulaciones para dosis estabilizantes de estatina
WO2007144785A2 (en) * 2006-03-26 2007-12-21 Uti Limited Partnership Ryanodine receptor inhibitors and methods relating thereto
US8022094B2 (en) * 2006-06-28 2011-09-20 Teva Pharmaceutical Industries Ltd. Carvedilol phosphate
US20080153896A1 (en) * 2006-07-14 2008-06-26 Gyan Chand Yadav Polymorphic Forms of an HMG-CoA Reductase Inhibitor and Uses Thereof
WO2008038301A1 (en) * 2006-09-26 2008-04-03 Morepen Laboratories Limited A process for the preparation of carvedilol
WO2008070496A2 (en) 2006-12-01 2008-06-12 Bristol-Myers Squibb Company N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
WO2008070072A2 (en) * 2006-12-01 2008-06-12 Mutual Pharmaceutical Company, Inc. Carvedilol forms, compositions, and methods of preparation thereof
US20090028935A1 (en) * 2006-12-01 2009-01-29 Kristin Arnold Carvedilol forms, compositions, and methods of preparation thereof
WO2008084494A1 (en) * 2007-01-08 2008-07-17 Matrix Laboratories Limited Novel polymorphic forms of carvedilol dihydrogen phosphate and process for preparing the same
AU2008207200B2 (en) * 2007-01-16 2011-02-17 Egalet Ltd Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
CZ302357B6 (cs) * 2007-01-26 2011-03-30 Zentiva, A. S. Zpusob cištení Carvedilolu
US20080207726A1 (en) * 2007-02-26 2008-08-28 Santiago Ini Process for the purification of carvedilol or its salts thereof
US20080249317A1 (en) * 2007-04-04 2008-10-09 Apotex Inc. Novel amorphous form of carvedilol phosphate and processes for the preparation thereof
WO2008142703A1 (en) * 2007-05-17 2008-11-27 Wanbury Limited A novel cost effective process for production of carvedilol phosphate
US8821928B2 (en) 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
EP2195292B1 (en) * 2007-08-21 2013-10-02 Lupin Ltd. Stable amorphous form of carvedilol dihydrogen phosphate with stabilizer
WO2009035535A2 (en) * 2007-09-07 2009-03-19 Scinopharm Taiwan Ltd. Method of crystallizing carvedilol phosphate and the product thereof
US20090076116A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched carvediolo
US20090111998A1 (en) * 2007-10-25 2009-04-30 Srinivas Reddy Gade Process for the preparation of carvedilol dihydrogen phosphate hemihydrate and pharmaceutical compositions thereof
ATE539769T1 (de) * 2008-03-04 2012-01-15 Lupin Ltd Stabile pharmazeutische zusammensetzungen mit carvedilol
WO2009115906A2 (en) * 2008-03-19 2009-09-24 Cadila Pharmaceuticals Ltd. An improved process for preparation of carvedilol involving halohydrin derivative
WO2009115902A1 (en) * 2008-03-19 2009-09-24 Cadila Pharmaceuticals Ltd. Process for the preparation of carvedilol via silyl protection of substituted amine
WO2009122425A1 (en) * 2008-04-04 2009-10-08 Shodhana Laboratories Limited Novel crystalline form of carvedilol dihydrogen phosphate and related processes
US7763645B2 (en) * 2008-05-23 2010-07-27 Wanbury Limited Carvedilol dihydrogen phosphate monohydrate
WO2010092589A2 (en) * 2008-05-26 2010-08-19 Alkem Laboratories Ltd. Process for preparation of amorphous carvedilol phosphate
CA2751667C (en) 2009-02-06 2016-12-13 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
AU2010265213B2 (en) 2009-06-24 2012-08-23 Egalet Ltd. Controlled release formulations
TWI415604B (zh) 2009-09-29 2013-11-21 Tsh Biopharm Corp Ltd 調控釋放卡菲蒂羅劑型
US20110229564A1 (en) * 2010-03-22 2011-09-22 Amneal Pharmaceuticals, L.L.C. Pharmaceutical Compositions Of Carvedilol Salts And Process For Preparation Thereof
US9932438B2 (en) 2011-12-16 2018-04-03 3M Innovative Properties Company Oxirane-containing bisanhydrohexitol derivatives and uses thereof
NZ704011A (en) 2012-07-06 2016-04-29 Egalet Ltd Abuse deterrent pharmaceutical compositions for controlled release
US8492426B1 (en) 2012-07-12 2013-07-23 Anis Ahmad Use of carvedilol for treatment of diabetes mellitus
SG11201507496UA (en) 2013-04-17 2015-11-27 Pfizer N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
US10357476B1 (en) 2018-10-30 2019-07-23 Anis Ahmad Method for treating coronary artery disease
JOP20210193A1 (ar) 2019-01-18 2023-01-30 Astrazeneca Ab مثبطات pcsk9 وطرق استخدامها
CN111170997A (zh) * 2019-12-31 2020-05-19 广州医科大学 咔唑类化合物及其制备方法和应用
CN113372260A (zh) * 2021-07-05 2021-09-10 大连蒙迪科技有限公司 一种卡维地洛杂质的合成方法
CN115960032A (zh) * 2021-10-08 2023-04-14 复旦大学 具有β-arrestin偏向性激动活性的芳氧丙醇胺类β-肾上腺素受体配基及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1834015A (en) * 1929-06-29 1931-12-01 Gen Aniline Works Inc Manufacture of hydroxy carbazoles
DE1152107B (de) * 1956-06-27 1963-08-01 Chem Fab Promonta G M B H Verfahren zur Herstellung von basisch substituierten Carbazolderivaten und deren Salzen
US3932424A (en) * 1970-06-15 1976-01-13 Richardson-Merrell Inc. Bis-basic ethers of carbazole
BE789072A (fr) * 1971-09-23 1973-03-21 Astra Laekemedel Ab Composes abaissant le taux de lipides du serum et leur obtention
AT336176B (de) * 1971-12-10 1977-04-25 Sandoz Ag Verfahren zur herstellung eines pharmazeutischen praparates
US3975398A (en) * 1973-08-01 1976-08-17 Boehringer Mannheim G.M.B.H. 9-Substituted 3-aminocarbazole compounds
DE2339396C2 (de) * 1973-08-03 1984-06-28 Boehringer Mannheim Gmbh, 6800 Mannheim N-substituierte 1-Amino-3-phenoxypropan-2-ole, deren Salze, Verfahren zu deren Herstellung sowie Arzneimittel, die diese Verbindungen enthalten
DE2424523A1 (de) * 1974-05-21 1975-12-11 Boehringer Mannheim Gmbh Neue 1,2,3,4-tetrahydrocarbazol-derivate und verfahren zu deren herstellung
US4152446A (en) * 1974-11-16 1979-05-01 Boehringer Mannheim Gmbh Aminopropanol compounds and compositions for the treatment of cardiac and circulatory diseases
US4076829A (en) * 1974-11-16 1978-02-28 Boehringer Mannheim Gmbh Aminopropanol compounds and compositions for the treatment of cardiac and circulatory diseases
DE2454406A1 (de) * 1974-11-16 1976-05-20 Boehringer Mannheim Gmbh Neue aminopropanol-derivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
US4115409A (en) * 1975-12-05 1978-09-19 Imperial Chemical Industries Limited Alkanolamine derivatives
GB1508208A (en) * 1975-12-05 1978-04-19 Ici Ltd Amide derivatives

Also Published As

Publication number Publication date
ATA276279A (de) 1984-01-15
IL57020A (en) 1982-07-30
SG52284G (en) 1985-03-29
FI70406B (fi) 1986-03-27
DD143607A5 (de) 1980-09-03
BG61419B2 (bg) 1997-07-31
DK154555C (da) 1989-06-19
FI791142A7 (fi) 1979-10-14
LT2628B (lt) 1994-04-25
DK141979A (da) 1979-10-14
AU522975B2 (en) 1982-07-08
CS227007B2 (en) 1984-04-16
CS420091A3 (en) 1992-04-15
SU810079A3 (ru) 1981-02-28
CA1129416A (en) 1982-08-10
AT375639B (de) 1984-08-27
LU88320I2 (de) 1994-05-04
JPS63258416A (ja) 1988-10-25
AU4582079A (en) 1979-10-18
HK2385A (en) 1985-01-18
IL57020A0 (en) 1979-07-25
EP0004920A1 (de) 1979-10-31
HU179433B (en) 1982-10-28
MX9203380A (es) 1992-09-01
ZA791732B (en) 1980-05-28
ES479396A1 (es) 1980-04-16
EP0004920B1 (de) 1981-08-05
US4503067A (en) 1985-03-05
FI70406C (fi) 1986-09-19
JPS54157558A (en) 1979-12-12
NL930110I2 (nl) 1994-12-01
DE2815926A1 (de) 1979-10-18
DE2960553D1 (en) 1981-11-05
DK154555B (da) 1988-11-28
NL930110I1 (nl) 1993-10-18

Similar Documents

Publication Publication Date Title
JPH0123462B2 (OSRAM)
EP0126449B1 (en) Cardioselective aryloxy- and arylthio-hydroxypropyl piperazinyl acetanilides wich affect calcium entry
FI62054B (fi) Foerfarande foer framstaellning av farmakologiskt vaerdefulla 1-aryloxi-2-hydroxi-3-alkinylaminopropaner
JP2601008B2 (ja) ナフチルオキサゾリドン誘導体、その製法及びその合成中間体
US4935414A (en) New indolylpropanols, processes for their preparation and their use, and preparations containing the compounds
US20070015745A1 (en) Cyclohexyl(alkyl)propanolamines, Preparation Method and Pharmaceutical Compositions Containing Same
JPH0625128A (ja) 新規なナフタレンアミドおよびナフタレンスルホンアミド化合物
EP0054304B1 (en) Alkylenedioxybenzene derivatives, acid addition salts thereof and a method for their preparation
EP0034116A2 (en) N-(3-phenoxy-2-hydroxypropyl)benzimidazole-1-alkanamines
EP0025727A1 (fr) Dérivés de l'indole, procédé pour leur préparation et médicaments les contenant
US3574749A (en) 1-(4-amidophenoxy)-3-amino-2-propanol derivatives
RU2557236C2 (ru) Способ получения соединений 2-(1-фенилэтил)изоиндолин-1-она
JPH10152460A (ja) ２−アミノ−１−（４−ヒドロキシ−２−メチルフェニル）プロパノール誘導体
JP3714978B2 (ja) ホスホリパーゼａ２阻害活性を有する新規カルボン酸誘導体
JPH0345042B2 (OSRAM)
JPH10195037A (ja) フェノール誘導体
KR100373957B1 (ko) 신규한아민유도체,그의제조방법및항부정맥제로서의용도
JP3492433B2 (ja) ３−（フェニルアルキルアミノアルキルオキシ）−５−フェニルピラゾール−化合物、その製造のための方法及び中間体、及びこれを含有する心臓循環作用薬剤
US4020071A (en) Derivatives of 1-phenoxy-3-amino-propan-2-ol
US4434174A (en) Treating cardiovascular diseases with N-(3-phenoxy-2-hydroxypropyl)benzimidazole-1-alkanamines
TW467881B (en) Guaiacoxypropanolamines with Α/β-adrenergic blocking activity
FR2551753A2 (fr) Benzotriazine-1,2,3-ones-4, procede de preparation et medicaments les contenant
JPS6344737B2 (OSRAM)
JPS5839832B2 (ja) 新規ピラジン化合物の製法
CS227047B2 (cs) Způsob výroby derivátů karbazol-4-yloxypropanolaminu